Copy Paste Quotes

AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger

Tie-up would be one of the biggest-ever pharmaceutical deals and create the world’s fourth-largest drugmaker

Britain’s biggest drugmaker AstraZeneca is understood to be in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group.

AstraZeneca, run by Pascal Soriot, its longtime chief executive, is the second-biggest listed company in the UK, with a market value of nearly £196bn before the news broke. BMS, headquartered in Princeton and known for its cancer treatments, is worth $133bn.

Continue reading...

Aug 3, 2026 AstraZeneca Pharmaceuticals industry Business

Need the full article?

Use the dedicated news page for the summary, then jump straight to the original source when you want the complete story.